Zobrazeno 1 - 10
of 93
pro vyhledávání: '"J. Berille"'
Autor:
Arnauld S. Gbenou, Sibille Everhard, Mayssam El-Mouhebb, Antoine Arnaud, Ines Vaz-Luis, Paul-Henri Cottu, Matteo Lambertini, P.A. Ganz, Arlindo R. Ferreira, Ann H. Partridge, J. Berille, Anne-Laure Martin, Florence Dalenc, Sarah Dauchy, Cécile Charles, Suzette Delaloge, A. Di Meglio, Florence Joly, Thierry Petit, Barbara Pistilli, Fabrice Andre, Philippe Rouanet, Stefan Michiels, Florence Lerebours, Charles Coutant
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(11)
Background In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus CT on the quality of life (QoL) of early BC patients is unknown. Here, we charact
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. Berille, M. Campone, Emmanuelle Bourbouloux, P. Fumoleau, P. Monin-Baroille, Nicolas Isambert, S. Maury
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:689-695
SR271425 is a novel DNA-binding cytotoxic agent with a broad spectrum of antitumor activity in preclinical models,across a variety of the schedule of administration. In toxicological studies, it has been reported to prolong QTc proportionally to C ma
Autor:
Pierre Ruffié, A. Monnier, T. Le Chevalier, N. Bougon, Jean-Yves Douillard, X.S. Sun, J. Berille, N. Ibrahim, L. Belli
Publikováno v:
European Journal of Cancer. 34:2032-2036
The activity of the combination of intravenous docetaxel 75 mg/m2 plus cisplatin 100 mg/m2 administered every 3 weeks for 3 cycles then every 6 weeks was investigated in 51 chemotherapy naive patients with locally advanced or metastatic non-small cel
Autor:
A. Riviere, M.L. Cerrina, S. Gouva, J. Berille, A. Monnier, Jean-Yves Douillard, A. Grandgirard, J.-P. Bizzari, J.L. Pujol, T. Le Chevalier
Publikováno v:
British Journal of Cancer
A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer. Eighty-seven patients with unresectable non-small-cell lung cancer took part in the study. Sevent
Autor:
Henri Roché, François Lokiec, J. Berille, Nicolas Isambert, Saik Urien, Keyvan Rezai, Véronique Diéras, Etienne Brain, Jacques Bonneterre
Publikováno v:
Cancer chemotherapy and pharmacology. 68(6)
The objectives of this study were to investigate the pharmacokinetics of intra-venous vinorelbine combined with lapatinib as well as the effect of covariates in breast cancer patients.Women with HER2 + locally advanced or metastatic breast cancer pro
Autor:
J. Gioanni, Patricia Formento, Gérard Milano, Jean-Louis Fischel, M. Berlion, J. P. Bizzari, J. Berille
Publikováno v:
Cancer Chemotherapy and Pharmacology. 28:448-454
The present study was designed to analyse the cytotoxic effects of the combination of fotemustine with 5-fluorouracil (5-FU) plus folinic acid (FA). Two human tumor cell lines were used; one line was derived from colon cancer (WIDR) and the other, fr
Publikováno v:
Cancer Chemotherapy and Pharmacology. 34:444-446
A total of 43 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a novel nitrosourea, fotemustine, given at 100 mg/m2 on days 1 and 8. Maintenance treatment consisted of a single injection of 100 mg/m2 g
Autor:
Jaafar Bennouna, V. Trillet-Lenoir, J. Berille, Alain Rivière, Etienne Lemarié, A. Monnier, Bernard Milleron, Jean-Yves Douillard, K Soussan-Lazard
Publikováno v:
European journal of cancer (Oxford, England : 1990). 36(9)
A phase II study was conducted to determine the efficacy and the safety of docetaxel combined with vinorelbine as first-line chemotherapy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). 39 patients, median age 54 years
Autor:
Croisile B, B. Giroux, C. Cotto, R. Riou, V. Trillet-Lenoir, J. Berille, Pierre-Jean Souquet, J. Brune, F. Turjman
Publikováno v:
European journal of cancer (Oxford, England : 1990). (1)
A phase II study was conducted in order to determine the feasibility and toxicity of cisplatin combined with the nitrosourea fotemustine in central nervous system metastases from non-small cell lung cancer. 31 chemotherapy-naive patients were include